Loading...

Invitae Corporation

NVTA•NYSE
Healthcare
Medical - Diagnostics & Research
$0.02
$-0.01(-35.59%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Financial performance has remained strong, with revenue growing from $122.45M in Q4 2022 to $121.24M in Q3 2023. Gross profit continued to perform well, with margins at 32% in the latest quarter. Operating income reached -$980.19M in Q3 2023, holding a steady -808% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$980.19M. Net income dropped to -$942.11M, keeping EPS at -$3.42. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;